Delay Looms For Axsome Therapeutics’ Entry Into Major Depressive Disorder Market With Lead Product

But Positive Data In Treatment-Resistant Depression

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.